BR112020001320A2 - combinações farmacêuticas que compreendem um anticorpo anti-bst-1 e um análogo de citidina - Google Patents

combinações farmacêuticas que compreendem um anticorpo anti-bst-1 e um análogo de citidina Download PDF

Info

Publication number
BR112020001320A2
BR112020001320A2 BR112020001320-0A BR112020001320A BR112020001320A2 BR 112020001320 A2 BR112020001320 A2 BR 112020001320A2 BR 112020001320 A BR112020001320 A BR 112020001320A BR 112020001320 A2 BR112020001320 A2 BR 112020001320A2
Authority
BR
Brazil
Prior art keywords
antibody
bst1
cancer
antibodies
seq
Prior art date
Application number
BR112020001320-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Cecilia SIMONELLI
Andrea PELLACANI
Monica BINASCHI
Daniela BELLAROSA
Corrado CARRISI
Original Assignee
Berlin-Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin-Chemie Ag filed Critical Berlin-Chemie Ag
Publication of BR112020001320A2 publication Critical patent/BR112020001320A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
BR112020001320-0A 2017-07-21 2018-07-20 combinações farmacêuticas que compreendem um anticorpo anti-bst-1 e um análogo de citidina BR112020001320A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1711785.4 2017-07-21
GBGB1711785.4A GB201711785D0 (en) 2017-07-21 2017-07-21 Antibodies
PCT/EP2018/069768 WO2019016371A1 (en) 2017-07-21 2018-07-20 PHARMACEUTICAL ASSOCIATIONS COMPRISING ANTI-BST-1 ANTIBODY AND A CYTIDINE ANALOG

Publications (1)

Publication Number Publication Date
BR112020001320A2 true BR112020001320A2 (pt) 2020-08-11

Family

ID=59771583

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020001320-0A BR112020001320A2 (pt) 2017-07-21 2018-07-20 combinações farmacêuticas que compreendem um anticorpo anti-bst-1 e um análogo de citidina

Country Status (22)

Country Link
US (1) US20200231694A1 (https=)
EP (1) EP3655033A1 (https=)
JP (1) JP2020527594A (https=)
KR (1) KR20200032162A (https=)
CN (1) CN111132697A (https=)
AR (1) AR112460A1 (https=)
AU (1) AU2018303241A1 (https=)
BR (1) BR112020001320A2 (https=)
CA (1) CA3070264A1 (https=)
CL (1) CL2020000175A1 (https=)
CO (1) CO2020001792A2 (https=)
EA (1) EA202090333A1 (https=)
GB (1) GB201711785D0 (https=)
IL (1) IL272096A (https=)
MA (1) MA49627A (https=)
MX (1) MX2020000752A (https=)
PH (1) PH12020550024A1 (https=)
SG (1) SG11202000390TA (https=)
TW (1) TW201907952A (https=)
UY (1) UY37815A (https=)
WO (1) WO2019016371A1 (https=)
ZA (1) ZA202000881B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004063494A1 (de) * 2004-12-23 2006-07-13 Tegenero Ag Antikörper
UA114478C2 (uk) * 2011-06-28 2017-06-26 Берлін-Хемі Аг Антитіло, яке специфічно зв'язується з bst1
GB201806084D0 (en) * 2018-04-13 2018-05-30 Berlin Chemie Ag Antibodies
CN114555123B (zh) * 2019-10-18 2024-04-02 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法

Also Published As

Publication number Publication date
GB201711785D0 (en) 2017-09-06
SG11202000390TA (en) 2020-02-27
ZA202000881B (en) 2021-08-25
MX2020000752A (es) 2020-08-17
AR112460A1 (es) 2019-10-30
EA202090333A1 (ru) 2020-05-06
IL272096A (en) 2020-03-31
WO2019016371A1 (en) 2019-01-24
CL2020000175A1 (es) 2020-06-12
TW201907952A (zh) 2019-03-01
CN111132697A (zh) 2020-05-08
EP3655033A1 (en) 2020-05-27
AU2018303241A1 (en) 2020-02-20
UY37815A (es) 2019-02-28
CO2020001792A2 (es) 2020-07-31
CA3070264A1 (en) 2019-01-24
MA49627A (fr) 2020-05-27
US20200231694A1 (en) 2020-07-23
PH12020550024A1 (en) 2021-02-15
KR20200032162A (ko) 2020-03-25
JP2020527594A (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
US9181339B2 (en) Antibodies specific to cadherin-17
US20150093392A1 (en) Antibodies
US10982005B2 (en) Antibodies to bone marrow stromal antigen 1
EP2726508B1 (en) Antibodies to adp-ribosyl cyclase 2
US20210032360A1 (en) Antibodies against bst1 for preventing or treating myelodysplastic syndrome
US20120231004A1 (en) Antibodies
BR112020001320A2 (pt) combinações farmacêuticas que compreendem um anticorpo anti-bst-1 e um análogo de citidina
HK1196138A (en) Antibodies to adp-ribosyl cyclase 2
HK1196138B (en) Antibodies to adp-ribosyl cyclase 2
RS56431B1 (sr) Antitela protiv adp-ribozil ciklaze 2
HK1164331B (en) Antibodies specific to cadherin-17
OA16799A (en) Antibodies to ADP-ribosyl cyclase 2.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2732 DE 16-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.